nRichDX to Exhibit & Present at AMP 2024 Annual Meeting, November 21-23


 

The emerging leader in liquid biopsy sample prep will have the latest automation & kits at exhibit booth #1321

VANCOUVER, BC, Oct. 17, 2024 /PRNewswire/ -- nRichDX®, will present new data, and exhibit at the Association for Molecular Pathology (AMP) Annual Meeting 2024. The meeting is November 19-23 at the Vancouver Convention Centre, in Vancouver, British Columbia, Canada. nRichDX will exhibit in booth #1321. The exhibits open at 11:15 AM on Thursday, November 21, and close at 1:30 PM on Saturday, November 23.

AMP Meeting attendees working in liquid biopsy and the extraction of analytes including ctDNA, ctRNA, cell-free total nucleic acid (cfTNA), and the enrichment of circulating tumor cells (CTCs) are encouraged to schedule a meeting or visit the nRichDX booth to see the latest liquid biopsy sample prep solutions and learn more about how extracting higher yields of these analytes can increase assay performance through better sensitivity and earlier detection of targeted oncology markers.

At least three posters planned for the meeting will include nRichDX solutions:

  • Enhanced Extraction and Preservation of Circulating Cell-Free RNA from 50 mL Cell-Free Urine, presented in collaboration with Agilent Technologies
  • The Mutational Landscape of Circulating Tumor Cells in Pancreatic Cancer, presented in collaboration with Dartmouth Hitchcock Medical Center
  • Clinical Validation of Cell-free DNA (cfDNA) Extraction from Whole Blood Plasma using the nRichDX® Revolution Max 20 Kit and Sample Prep System, presented in collaboration with Dartmouth Hitchcock Medical Center

AMP attendees are encouraged to schedule an appointment to meet with nRichDX people at the meeting or schedule an in-booth discussion and demo. For more information about nRichDX's schedule at the AMP 2024 Annual Meeting, please visit www.nrichdx.com/amp2024.

[AMP 2024 Annual Meeting website]

About nRichDX:

nRichDX® provides kits and automated solutions for isolating cfDNA, cfRNA, and CTCs. The patented Revolution Sample Prep System is engineered specifically for liquid biopsy applications and isolating analytes from blood, plasma, urine, and other biofluids. It is the first and only high-yield, high-recovery, IVD-labeled sample prep platform to process from as little as 1 mL to 100 mL in a single extraction using the company's patented Revolution nRicher™ Cartridges. Unlike other methods, Revolution sample prep doesn't require yield-lowering sample preconcentration, eluate pooling, sample transfer, or sample re-elution steps. nRichDX helps solve one of precision medicine's greatest problems – – inaccurate or incomplete diagnostic results for liquid biopsy-based applications due to insufficient analyte. nrichdx.com.